RushNet Inc. Cancellation of Proposed Reverse Split
RushNet, Inc. (OTC PINK:RSHN) announced the cancellation of the proposed Reverse Split (RS) in a move aimed at stabilizing share value.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
RushNet, Inc. (OTC PINK:RSHN) announced the cancellation of the proposed Reverse Split (RS) in a move aimed at stabilizing share value. The firm will notify the Colorado Secretary of State to formalize this decision. As a National Independent Clinical Reference Laboratory, heliosDX offers various testing services and aims to expand its reach while maintaining high-quality reporting standards. However, potential investors are cautioned about the uncertainties related to COVID-19's impact on the company's operations.
Positive
- Cancellation of the proposed Reverse Split is a positive step for share value stability.
- heliosDX's extensive testing services in 44 states indicate strong market presence.
Negative
- Uncertainty regarding the COVID-19 pandemic may adversely affect future operations and financial performance.
Details
News Market Reaction – RSHN
The recorded move for RSHN in the trading session of this news was +20.00%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ALPHARETTA, GA / ACCESSWIRE / June 9, 2021 / RushNet, Inc. (OTC PINK:RSHN) ("RushNet") with merger/acquisition target heliosDX, is pleased to announce the official cancelation of the proposed Reverse Split (RS). The company will file with the Colorado Secretary of State to reflect such cancelation.
About HeliosDx:
heliosDX is a National Independent Clinical Reference Laboratory offering High-Complexity Urine Drug Testing (UDT), Behavioral Drug Testing, Allergy Droplet Cards, Oral Fluids, Infectious Disease (PCR), and NGS Genetic Testing. We are contracted in 44 of the lower 48 states and looking to expand our reach and capabilities. Always staying ahead of the curve, by continually investing in our infrastructure with the most efficient scientific proven instruments, and latest cutting-edge software for patient and physician satisfaction. This allows heliosDX to provide physicians fast and accurate reporting meeting and exceeding industry benchmarks. We excel in patient and client care through physician designed panels that aid in testing compliance and reporting education.
Contact: Ashley Sweat
asweat@heliosdx.com
www.heliosdx.com (Under Development)
Twitter: @dx_helios
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.
Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives -
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.
The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment, or other strategies with regard to COVID-19.
The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.
We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.
SOURCE: RushNet, Inc.
View source version on accesswire.com:
https://www.accesswire.com/651107/RushNet-Inc-Cancellation-of-Proposed-Reverse-Split
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.